The role of stereotactic body radiation therapy and its integration with systemic therapies in metastatic kidney cancer: a multicenter study on behalf of the AIRO (Italian Association of Radiotherapy and Clinical Oncology) genitourinary study group-Reference-Cited by-同舟云学术

The role of stereotactic body radiation therapy and its integration with systemic therapies in metastatic kidney cancer: a multicenter study on behalf of the AIRO (Italian Association of Radiotherapy and Clinical Oncology) genitourinary study group

Published:2021-11-08 Issue:6 Volume:38 Page:527-537
ISSN:0262-0898
Container-title:Clinical & Experimental Metastasis
language:en
Short-container-title:Clin Exp Metastasis

Author:

Franzese Ciro^ORCID,Marvaso Giulia,Francolini Giulio,Borghetti Paolo,Trodella Luca Eolo,Sepulcri Matteo,Matrone Fabio,Nicosia Luca,Timon Giorgia,Ognibene Lucia,Vinciguerra Annamaria,Alongi Filippo,Bortolus Roberto,Corti Luigi,Ramella Sara,Magrini Stefano Maria,Livi Lorenzo,Jereczek-Fossa Barbara Alicja,Scorsetti Marta,Arcangeli Stefano

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology,General Medicine

Link

https://link.springer.com/content/pdf/10.1007/s10585-021-10131-w.pdf

Reference31 articles.

1. AIOM-Airtum I numeri del cancro in Italia 2018 n.d.

2. Srigley J, Delahunt B, Eble J, Egevad L, Epstein J, Grignon D et al (2013) The international society of urological pathology (ISUP) vancouver classification. Am J Surg Pathol 37:1469–1489

3. DeCastro GJ, McKiernan JM (2008) Epidemiology, clinical staging, and presentation of renal cell carcinoma. Urol Clin North Am 35:581–592. https://doi.org/10.1016/j.ucl.2008.07.005

4. Eggener SE, Yossepowitch O, Pettus JA, Snyder ME, Motzer RJ, Russo P (2006) Renal cell carcinoma recurrence after nephrectomy for localized disease: Predicting survival from time of recurrence. J Clin Oncol 24:3101–3106. https://doi.org/10.1200/JCO.2005.04.8280

5. Franzese C, Franceschini D, Di Brina L, D’Agostino GR, Navarria P, Comito T et al (2019) Role of stereotactic body radiation therapy for the management of oligometastatic renal cell carcinoma. J Urol 201:70–76. https://doi.org/10.1016/j.juro.2018.08.049

Cited by 20 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Stereotactic ablative radiotherapy for oligoprogressive solid tumours: A systematic review and meta-analysis;Radiotherapy and Oncology;2024-11

2. Predictive Factors for Long-Term Disease Control in Systemic Treatment-Naïve Oligorecurrent Renal Cell Carcinoma Treated with Up-Front Stereotactic Ablative Radiotherapy (SABR);Cancers;2024-08-25

3. Stereotactic Radiotherapy for Penile Metastasis: Case Report and Systematic Literature Review;Oncology Research and Treatment;2024-05-18

4. Delphi consensus on stereotactic ablative radiotherapy for oligometastatic and oligoprogressive renal cell carcinoma—a European Society for Radiotherapy and Oncology study endorsed by the European Association of Urology;The Lancet Oncology;2024-05

5. The efficacy and safety of stereotactic body radiotherapy combined with systematic therapy for metastatic renal cell carcinoma: a systematic review and meta‐analysis;MedComm;2024-04-24